Germline BRCA1 mutations predispose to pancreatic adenocarcinoma.

Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. Abstract Text:

Although the association of germline BRCA2 mutations with pancreatic adenocarcinoma is well established, the role of BRCA1 mutations is less clear. We hypothesized that the loss of heterozygosity at the BRCA1 locus occurs in pancreatic cancers of germline BRCA1 mutation carriers, acting as a "second-hit" event contributing to pancreatic tumorigenesis. Seven germline BRCA1 mutation carriers with pancreatic adenocarcinoma and nine patients with sporadic pancreatic cancer were identified from clinic- and population-based registries. DNA was extracted from paraffin-embedded tumor and nontumor samples. Three polymorphic microsatellite markers for the BRCA1 gene, and an internal control marker on chromosome 16p, were selected to test for the loss of heterozygosity. Tumor DNA demonstrating loss of heterozygosity in BRCA1 mutation carriers was sequenced to identify the retained allele. The loss of heterozygosity rate for the control marker was 20%, an expected baseline frequency. Loss of heterozygosity at the BRCA1 locus was 5/7 (71%) in BRCA1 mutation carriers; tumor DNA was available for sequencing in 4/5 cases, and three demonstrated loss of the wild-type allele. Only 1/9 (11%) sporadic cases demonstrated loss of heterozygosity at the BRCA1 locus. Loss of heterozygosity occurs frequently in pancreatic cancers of germline BRCA1 mutation carriers, with loss of the wild-type allele, and infrequently in sporadic cancer cases. Therefore, BRCA1 germline mutations likely predispose to the development of pancreatic cancer, and individuals with these mutations may be considered for pancreatic cancer-screening programs.

Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Human genetics

VOLUME: 124

Page Numbers: 271-8

Journal Abbreviation: Hum. Genet.

ISSN: 1432-1203

DAY: 2

MONTH: 09

YEAR: 2008

Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7613873

Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Germline BRCA1 mutations predispose to pancreatic adenocarcinoma.

AFFILIATION: Gallinger Lab, Samuel Lunenfeld Research Institute, 60 Murray Street, Toronto, ON, M5G1X5, Canada. wigdan.al.sukhni@utoronto.ca

Country: Germany

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Hum Genet

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Germline BRCA1 mutations predispose to pancreatic adenocarcinoma Related Publications

• Allergies are associated with reduced pancreas cancer risk: A population-based case-control study in Ontario, Canada.
• Colorectal cancer risks in relatives of young-onset cases: is risk the same across all first-degree relatives?
• Does early colectomy increase desmoid risk in familial adenomatous polyposis?
• Germ-line DNA copy number variation frequencies in a large North American population.
• Germline BRCA1 mutations predispose to pancreatic adenocarcinoma.
• Germline EPHB2 receptor variants in familial colorectal cancer.
• Hereditary colorectal cancer syndromes: familial adenomatous polyposis and lynch syndrome.
• Pathological features of colorectal carcinomas in MYH-associated polyposis.
• Sclerosing pancreatitis presenting as a periampullary tumour.
• Survival after liver resection for metastatic colorectal carcinoma in a large population.
• The P239S palladin variant does not account for a significant fraction of hereditary or early onset pancreas cancer.